Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma Post author:andrewkaretas Post published:December 22, 2020 Post category:BCMA/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma
Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML Post author:andrewkaretas Post published:December 18, 2020 Post category:CD70/Scientific Publications Continue ReadingInvestigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML
First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study) Post author:andrewkaretas Post published:December 9, 2020 Post category:BCMA/Scientific Publications Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery Post author:andrewkaretas Post published:October 18, 2020 Post category:FLT3/Scientific Publications Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
American Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:June 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs
American Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer Post author:andrewkaretas Post published:June 18, 2020 Post category:DLL3/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer
American Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:May 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs
American Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study Post author:andrewkaretas Post published:May 1, 2020 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study
Toward “Off-the-Shelf” Allogeneic CAR T Cells Post author:andrewkaretas Post published:April 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingToward “Off-the-Shelf” Allogeneic CAR T Cells
American Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia Post author:andrewkaretas Post published:December 18, 2019 Post category:FLT3/Scientific Publications Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia
